Edition:
United States

CymaBay Therapeutics Inc (CBAY.O)

CBAY.O on Consolidated Issue listed on NASDAQ Capital Market

7.75USD
21 Jul 2017
Change (% chg)

$0.45 (+6.16%)
Prev Close
$7.30
Open
$7.30
Day's High
$7.94
Day's Low
$7.16
Volume
2,637,836
Avg. Vol
684,260
52-wk High
$7.94
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

CymaBay announces pricing of public offering of common stock
Wednesday, 19 Jul 2017 08:30am EDT 

July 19 (Reuters) - CymaBay Therapeutics Inc -:CymaBay announces pricing of public offering of common stock.Says public offering of 13.0 million common shares priced at $6.50 per share.  Full Article

Cymabay announces proposed public offering of 10.0 mln common shares
Monday, 17 Jul 2017 04:14pm EDT 

July 17 (Reuters) - Cymabay Therapeutics Inc :Cymabay announces proposed public offering of common stock.Says offering 10.0 million common shares.Cymabay Therapeutics Inc - anticipates using net proceeds from offering to fund ongoing development of seladelpar.Cymabay Therapeutics Inc - ‍intends to offer and sell 10 million shares of its common stock in an underwritten public offering​.  Full Article

CymaBay announces positive interim results from low-dose phase 2 study of seladelpar
Monday, 17 Jul 2017 07:30am EDT 

July 17 (Reuters) - Cymabay Therapeutics Inc ::CymaBay announces positive interim results from its ongoing low-dose phase 2 study of seladelpar in patients with primary biliary cholangitis.CymaBay Therapeutics Inc says strong reduction in alkaline phosphatase of 39pct (5 mg) and 45pct (10 mg) at week 12.CymaBay Therapeutics Inc says FDA agrees to extend dosing of 5 mg and 10 mg beyond six months.CymaBay Therapeutics Inc says potential for superior efficacy and better tolerability than existing second-line therapy in study.CymaBay Therapeutics Inc says in study there were no serious adverse events and no safety transaminase signal was observed at either dose.CymaBay Therapeutics Inc says fda has agreed to allow continuation of seladelpar treatment beyond six months for 5 mg and 10 mg doses.  Full Article

Cymabay reports Q1 loss per share $0.20
Thursday, 11 May 2017 04:01pm EDT 

May 11 (Reuters) - Cymabay Therapeutics Inc :Cymabay reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.20.Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

CymaBay reports Q4 and year end 2016 financial results
Thursday, 23 Mar 2017 04:01pm EDT 

CymaBay Therapeutics Inc - : CymaBay reports fourth quarter and year end 2016 financial results . Q4 loss per share $0.30 . Q4 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S . As of December 31, 2016, CymaBay had cash, cash equivalents and marketable securities of approximately $17.0 million .Believes that funds, among others, will allow co to continue operations through at least next twelve months.  Full Article

Cymabay announces pricing of public offering of common stock
Thursday, 2 Feb 2017 09:15am EST 

Cymabay Therapeutics Inc : Cymabay announces pricing of public offering of common stock .Says public offering of 5.18 million common shares priced at $1.93per share.  Full Article

CymaBay reports proposed public offering of common stock
Wednesday, 1 Feb 2017 04:01pm EST 

Cymabay Therapeutics Inc : CymaBay announces proposed public offering of common stock .Anticipates using net proceeds from offering to fund ongoing development of seladelpar.  Full Article

Kowa Pharmaceuticals enters agreement with CymaBay Therapeutics to license gout compound
Tuesday, 3 Jan 2017 04:01pm EST 

Kowa Pharmaceuticals America Inc : Kowa Pharmaceuticals America Inc announces agreement with CymaBay Therapeutics to license gout compound . Kowa Pharmaceuticals America - will license product from CymaBay, which has completed a combined 17 phase 1 and phase 2 studies in over 1,100 subjects . Kowa Pharmaceuticals America - CymaBay will receive pre-specified milestone and sales-related payments . Kowa Pharmaceuticals America - under terms of agreement, co will manage Phase 3 clinical development program for arhalofenate .Kowa Pharmaceuticals America - under terms of agreement, co will commercialize arhalofenate upon approval of arhalofenate in combination with febuxostat in U.S..  Full Article

Cymabay reports second quarter 2016 financial results
Tuesday, 9 Aug 2016 04:01pm EDT 

Cymabay Therapeutics Inc : Q2 loss per share $0.30 . Cymabay reports second quarter 2016 financial results .Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Cymabay qtrly loss per share $0.29
Wednesday, 11 May 2016 04:05pm EDT 

Cymabay Therapeutics Inc : Qtrly loss per share $0.29 .Cymabay reports first quarter 2016 financial results.  Full Article